Iqirvo (elafibranor) receives FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis – Ipsen
Ipsen announced that the FDA has granted accelerated approval for Iqirvo (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid… read more.
